Abstract: A tablet (10) for the controlled release of a drug. The tablet (10) is in the form of an asymmetrically coated tablet so that immediate release or time-delayed release times can be precisely controlled and the extended release slab may provide zero-order or first-order extended release and pulsatile release depending on the excipients used in the tablet formulations. The core (11) of the tablet (10) is coated with an asymmetrical coating, that is, a coating with regions (14, 15) having different properties. The coatings may include drugs in varying concentrations. Further, different regions (14, 15) of the coating may have different rates of dissolution. The core (11) of the tablet (10) may be provided with a constant cross-sectional area (12) along a longitudinal length of the tablet, a coating having a first region (14) with a more rapid rate of dissolution than a second region (15). The dissolution of the first region (14) exposes only the cross-sectional area (12) to the dissolution medium. The second region (15) of the coating prevents any other portion of the core (11) of the tablet from being exposed to the dissolution medium. Therefore, since the cross-sectional area (12) remains constant as it is dissolved, the rate of release of the drug from the core (11) of the tablet remains constant. The cross-sectional area (12) may be of any geometrical configuration so long as the area remains constant as the core (11) dissolves.
Description

Asymmetrically Coated Tablet

5 Technical Field

The present invention relates to pharmaceutical dosage forms and in, particularly, to a tablet containing a drug having a precisely predetermined release kinetics.

10 Background Art

There have been various attempts made to create extended release dosage forms for orally administering drugs. Some dosage forms tend to release the drug at rates that do not correlate well with the needs of the patient. For example, a particular dosage form may release a large amount of the drug rapidly upon ingestion where a more constant rate of release is desirable. In other situations, varying release rates may be desirable. Additional background information on the art of controlling release rates of drugs in orally administered dosage forms is found in U.S. Patent Numbers 5,945,125 and 6,1 10,500 and U.S. Published Patent Application No. US2005/0025829, the disclosures of which are incorporated herein by reference. Dosage forms typically comprise the drug; that is, the pharmacologically active substance, dispersed in various excipients including polymers whose rates of dissolution are known. As the tablet is dissolved, the drug is released at a predicted rate. Coating excipients having various rates of dissolution have also been used for time delayed release of drugs.

20 Common oral extended release or pulsatile release dosage forms include tablets, caplets, and capsules containing small spherical pellets. Such dosage forms typically have the combined geometry of slabs and cylinders, which tend to produce varying release rates. As the tablet is dissolved, the amount of surface area exposed to the dissolution medium changes, thereby changing the rate at which the dissolution occurs and thus the rate of release of the drug. In certain situations, it is desirable that the rate of release of drugs has a zero-order kinetics; that is, the drug is released at a constant or nearly constant rate. However, the rate of drug release from conventional dosage forms typically does not follow zero-order kinetics and thus the drug release rate decreases as release time progresses.
While constant drug release rates are desirable in certain circumstances, it is more generally desirable to be able to customize the kinetics of drug release. For example, a rapid initial release (a burst) may desirably be followed by a period of constant release. In other examples, it might be desirable to delay the release of the drug for a period of time or to release a pulse of the drug after a period of constant release.

As noted above, in order to obtain immediate release followed by extended release or time-delayed release followed by extended release or time-delayed release followed by pulsatile release, dosage forms are coated uniformly with appropriate coating excipients with or without drugs dispersed in the coating. Once the coating layer disappears (or dissolves), the extended release tablet shape is exposed to the dissolution medium and thus the same kinetic problems of other dosage forms are encountered.

These and other problems of the prior art are addressed by the present invention as described following.

Disclosure of the Invention

The present invention uses asymmetrically coated tablets so that immediate release or time-delayed release times can be precisely controlled and the extended release tablet may provide zero-order or first-order extended release and pulsatile release depending on the excipients used in the tablet formulations. Immediate release or time-delayed release time can be precisely determined. Extended release kinetics can be manipulated as a dosage form designer wishes.

The core of the tablet in the present invention is coated with an asymmetrical coating, that is a coating with regions having different properties. The coatings may include drugs in varying concentrations. Further, different regions of the coating may have different rates of dissolution. In one embodiment of the present invention, the core of the tablet is provided with a constant cross-sectional area along a longitudinal length of the tablet. So long as only the cross-sectional area is exposed to the dissolution medium, zero-order kinetics; i.e., a constant release rate, may be achieved. This is accomplished by providing the tablet with a coating having a first region with a more rapid rate of dissolution than a second region. The dissolution of the first region exposes only the cross-sectional area to the dissolution medium. The second region of the coating prevents any other portion of the core of the tablet from
being exposed to the dissolution medium, at least until the core of the tablet is
dissolved. Therefore, since the cross-sectional area remains constant as it is
dissolved, the rate of release of the drug from the core of the tablet remains
constant. The cross-sectional area may be of any geometrical configuration so long
as the area remains constant as the core dissolves.

**Brief Description of the Drawings**

Fig. 1 is a graph of the release rate of a drug from an asymmetrically coated
table of the present invention superimposed on a graph of the release rate of a
commercially-available brand of anti-hypertensive pharmaceutical, Toprol XL®
(Astrazeneca LP, Wayne, Pennsylvania USA).

Fig. 2 is a graph of the release rate of a drug from a second embodiment of
the asymmetrically coated table of the present invention superimposed on a graph of
the release rate of a commercially-available brand of antidiabetic preparation,
Glucotrol XL® (Pfizer Inc., New York, New York USA).

Fig. 3 is a graph of the release rate of a drug from a third embodiment of the
asymmetrically coated table of the present invention superimposed on a graph of the
release rate of a commercially-available brand of pharmaceutical for the treatment of
cardiovascular conditions, Covera HS® (G.D. Searle LLC, North Peapack, New
Jersey USA).

Fig. 4 is a graph of the release rate of a drug from a fourth embodiment of the
asymmetrically coated table of the present invention superimposed on a graph of the
release rate of a commercially-available brand of antidepressant pharmaceutical,
Effexor XR® (Wyeth, Madison, New Jersey USA).

Fig. 5 is a graph of the release rate of a drug from a fifth embodiment of the
asymmetrically coated table of the present invention superimposed on a graph of the
release rate of a commercially-available brand of adrenergic beta-receptor blocking
agent, Inderal® LA (Wyeth, Madison, New Jersey USA).

Fig. 6 is a graph of the release rate of a drug from a sixth embodiment of the
asymmetrically coated table of the present invention superimposed on a graph of the
release rate of a commercially-available brand of pharmaceutical for the treatment of
digestive tract disorders, Asacol® (Medeva Pharma Schweiz AG, Liestal,
Switzerland).
Figs. 7A-C are elevation sectional views of a first embodiment of the asymmetrically coated table of the present invention. The core of the tablet has a cross-sectional area that is constant along a longitudinal length of the core. This area may be of any geometrical configuration so long as the area remains constant as the core dissolves. This ensures a constant release rate; i.e., zero-order kinetics. Fig. 7A shows the tablet with two coating regions, a first region comprising a water soluble polymer and a second region comprising a water insoluble polymer. In alternative embodiments, the first region may comprise a water soluble polymer and the second region a water soluble polymer, where the first region has a greater rate of dissolution than the second region. The first region incorporates a drug so that the rapid dissolution of the first region as shown in Fig. 7B provides a burst release of the drug as shown by the non-zero fractional release at time=0 in the graph of Fig. 1. With the dissolution of the first region, the drug-containing core is exposed to the dissolution medium and the drug begins to be released at a constant rate as shown by the essentially linear portion of the fractional release curve of Fig. 1 until the core is completely dissolved as shown in Fig. 7C.

Figs. 8A-C are elevation sectional views of a second embodiment of the asymmetrically coated table of the present invention. The core of the tablet has a cross-sectional area that is constant along a longitudinal length of the core. This area may be of any geometrical configuration so long as the area remains constant as the core dissolves. This ensures a constant release rate; i.e., zero-order kinetics. Fig. 8A shows the tablet with two coating regions, a first region comprising a water soluble polymer and a second region comprising a water insoluble polymer. In alternative embodiments, the first region may comprise a water soluble polymer and the second region a water soluble polymer, where the first region has a greater rate of dissolution than the second region. The rate of dissolution of the first region is selected so that the release of the drug from the core is delayed for an interval of time as shown in the time axis of Fig. 2. With the dissolution of the first region as shown in Fig. 8B, the core is exposed to dissolution and the drug begins to be released at a constant rate as shown by the essentially linear portion of the fractional release curve of Fig. 2 until completely dissolved as shown in Fig. 8C.

Figs. 9A-C are elevation sectional views of a third embodiment of the asymmetrically coated table of the present invention. The core of the tablet has a constant cross-sectional area along a longitudinal length of the core. This area may
be of any geometrical configuration so long as the area remains constant as the core
dissolves. This ensures a constant release rate; i.e., zero-order kinetics. Fig. 9A
shows the tablet with two coating regions, a first region comprising a water soluble
polymer and a second region comprising a water insoluble polymer. In alternative
embodiments, the first region may comprise a water soluble polymer and the second
region a water soluble polymer, where the first region has a greater rate of
dissolution than the second region. The rate of dissolution of the first region is
selected so that the release of the drug from the core tablet is delayed for an interval
of time as shown in the time axis of Fig. 3. The delay is greater than the delay of the
embodiment shown in Fig. 2. The greater delay can be achieved by selecting the
coating material or by a greater thickness. With the dissolution of the first region as
shown in Fig. 9B, the core is exposed to the dissolution media and begins to be
released at a constant rate as shown by the essentially linear portion of the fractional
release curve of Fig. 3 until completely dissolved as shown in Fig. 9C.

Figs. 10A-D are elevation sectional views of a fourth embodiment of the
asymmetrically coated tablet of the present invention. The core of the tablet has a
constant cross-sectional area along a longitudinal length of the core. This area may
be of any geometrical configuration so long as the area remains constant as the drug
dissolves. This ensures a constant release rate; i.e., zero-order kinetics. However,
unlike the embodiments described above, the embodiment of Figs. 10A-D has a core
formed in two parts. The two parts are formulated to give two different release rates.
The rate from the first part is set to be greater than the release rate from the second
part. As in the previous embodiments, Fig. 10A shows the tablet with two coating
regions, a first region comprising a water soluble polymer and a second region
comprising a water insoluble polymer. In alternative embodiments, the first region
may comprise a water soluble polymer and the second region a water soluble
polymer, where the first region has a greater rate of dissolution than the second
region. The rate of dissolution of the first region as shown in Fig. 10B is selected so
that no appreciable delay occurs in the release of the drug from the first part of the
core tablet. The release of the drug from the first part of the core tablet is shown by
the initial steep linear rise in the fractional release as shown in Fig. 4. This time
period corresponds to the situation illustrated in Fig. 10B. When the first part of the
core has been completely dissolved, the second part begins to dissolve (Fig. 10C) at
a less rapid but still essentially linear rate as shown by the less steeply pitched part
of the curve of Fig. 4 until the drug from the second part is completely dissolved as shown in Fig. 1OD.

Figs. 11A-C are elevation sectional views of a fifth embodiment of the asymmetrically coated tablet of the present invention. This embodiment is similar to the embodiments of Figs. 1-4 and 6 where the first coating dissolves as shown in Fig. 11B, but in this embodiment the core of the tablet is made with a water insoluble polymer rather than the water soluble polymers of Figs. 1-4 and 6. By the use of water insoluble polymers, the drug release as shown in Fig. 11C is determined by Fickian kinetics according to the graph of Fig. 5.

Figs. 12A-C are elevation sectional views of a sixth embodiment of the asymmetrically coated tablet of the present invention. In this embodiment as shown in Fig. 12A, the first coating region is made of an enteric polymer which is soluble at an enteric pH of 5.0 and higher. Depending on the thickness of the polymer, the dissolution of the first region is delayed until the tablet has been exposed to an enteric pH for a given period of time. After dissolution of the first region as shown in Fig. 12B, the core dissolves as shown in Figs. 6 and 12C.

Fig. 13 is an elevation view of a die apparatus for forming the tablet of the present invention using a powder coating technique. The tablet and tool for holding the tablet are shown in cross-section.

Best Mode for Carrying Out the Invention

The preferred embodiments of the invention are described herein with reference to Fig. 1-12C.

A first embodiment of the present invention is described with respect to Figs. 1 and Figs. 7A-C. Fig. 1 is a graph of the release rate of a drug from an asymmetrically coated tablet 10 of the present invention superimposed for comparison on a graph of the release rate of a commercially available brand of pharmaceutical, Toprol XL®. Fig. 1 thus illustrates how the tablet 10 of the present invention may be formed to match a specific release rate of a known commercially-available product. The tablet 10 comprises a core 11 having a drug dispersed in various excipients including polymers as known in the art to allow the core 11 to dissolve at a predicted rate and therefore provide an extended release of the drug.

Figs. 7A-C are elevation sectional views of the first embodiment where the core 11 of the tablet 10 has a cross-sectional area 12 that is constant along a
longitudinal length 13 of the tablet 10. This area 12 may be of any geometrical configuration so long as the area 12 remains constant as the core 11 dissolves. This ensures a constant release rate; i.e., zero-order kinetics. Fig. 7A shows the tablet 10 with two coating regions, a first region 14 comprising a water soluble polymer and a second region 15 comprising a water insoluble polymer. Alternatively, the first region 14 may comprise a water soluble polymer and the second region 15 may also comprise a water soluble polymer, where the first region 14 has a greater rate of dissolution than the second region 15. The first region 14 covers only the cross-sectional area 12 and therefore only the cross-sectional area 12 is exposed to the dissolution medium following the dissolution of the first region 14. The second region 15 does not dissolve or has a delayed dissolution so that no other part of the core 11 is exposed to the dissolution medium at least until the core 11 is completely dissolved. In this embodiment, the first region 14 of the coating incorporates a drug so that the rapid dissolution of the first region 14 as shown in Fig. 7B provides a burst release of the drug as shown by the non-zero fractional release at time = 0 in the graph of Fig. 1. With the dissolution of the first region 14, the core is exposed to the dissolution medium and the drug begins to be released at a constant rate as shown by the essentially linear portion of the fractional release curve of Fig. 1. Various means are known in the art to effect different rates of release of a drug from a coating material, including using dissolving and non-dissolving but permeable materials.

A second embodiment of the present invention is described with respect to Figs. 2 and Figs. 8A-C. Fig. 2 is a graph of the release rate of a drug from a second embodiment of the asymmetrically coated tablet 10 of the present invention superimposed on a graph of the release rate of a commercially-available brand of pharmaceutical, Glucotrol XL®.

Figs. 8A-C are elevation sectional views of the second embodiment of the asymmetrically coated tablet 10 of the present invention. As with the first embodiment, the core 11 of the tablet 10 has a cross-sectional area 12 that is constant along a longitudinal length of the core 11. This area 12 may be of any geometrical configuration so long as the area 12 remains constant as the core 11 dissolves. This ensures a constant release rate; i.e., zero-order kinetics. Fig. 8A shows the tablet 10 with two coating regions, a first region 14 comprising a water soluble polymer and a second region 15 comprising a water insoluble polymer.
Alternatively, the first region 14 may comprise a water soluble polymer and the second region 15 may also comprise a water soluble polymer, where the first region 14 has a greater rate of dissolution than the second region 15. The rate of dissolution of the first region 14 is selected so that the release of the drug from the core 11 is delayed for an interval of time as shown in the time axis of Fig. 2. As known in the art, the delay may be determined by the thickness of the first region 12 or by selecting water-soluble polymers for the first region 12 having greater or lesser molecular weights. Higher molecular weight polymers dissolve more slowly than lower molecular weight polymers. With the dissolution of the first region 14, the core 11 is exposed to dissolution and the drug begins to be released at a constant rate as shown by the essentially linear portion of the fractional release curve of Fig. 2.

A third embodiment of the present invention is described with respect to Figs. 3 and Figs. 9A-C. Fig. 3 is a graph of the release rate of a drug from a third embodiment of the asymmetrically coated tablet 10 of the present invention superimposed on a graph of the release rate of a commercially available brand of pharmaceutical, Covera HS®.

Figs. 9A-C are elevation sectional views of a third embodiment of the asymmetrically coated tablet 10 of the present invention. As with the previous embodiments, the core 11 of the tablet 10 has a cross-sectional area 12 that is constant along a longitudinal length of the core 11. This area 12 may be of any geometrical configuration so long as the area 12 remains constant as the core 11 dissolves. This ensures a constant release rate; i.e., zero-order kinetics. Fig. 9A shows the tablet 10 with two coating regions, a first region 14 comprising a water soluble polymer and a second region 15 comprising a water insoluble polymer.

Alternatively, the first region 14 may comprise a water soluble polymer and the second region 15 may also comprise a water soluble polymer, where the first region 14 has a greater rate of dissolution than the second region 15. The rate of dissolution of the first region 14 is selected so that the release of the drug from the core 11 is delayed for an interval of time as shown in the time axis of Fig. 3. The delay is greater than the delay of the embodiment shown in Fig. 2. The greater delay can be achieved as described by selecting a higher molecular weight polymer for the coating material or by selecting a greater thickness. With the dissolution of the first region 14, the core 11 is exposed to the dissolution media and the drug
begins to be released at a constant rate as shown by the essentially linear portion of
the fractional release curve of Fig. 3.

A fourth embodiment of the present invention is described with respect to
Figs. 4 and Figs. 10A-D. Fig. 4 is a graph of the release rate of a drug from a fourth
embodiment of the asymmetrically coated tablet 10 of the present invention
superimposed on a graph of the release rate of a commercially-available brand of
pharmaceutical, Effexor XR®.

Figs. 10A-D are elevation sectional views of the fourth embodiment of the
asymmetrically coated tablet 10 of the present invention. The core 11 of the tablet
10 has a constant cross-sectional area 12 as described previously. However, unlike
the embodiments described above, the embodiment of Figs. 10A-D has a core 11
formed in two parts. The two parts are formulated to give two different release rates
for the drug. In this example, the rate from the first part 16 is set to be greater than
the release rate from the second part 17; however, the present invention
contemplates that either part may have greater release rates than the other. Further,
any number of parts may be employed as a particular situation requires. As in the
previous embodiments, Fig. 10A shows the tablet 10 with two coating regions, a first
region 14 comprising a water soluble polymer and a second region 15 comprising a
water insoluble polymer. Alternatively, the first region 14 may comprise a water
soluble polymer and the second region 15 a water soluble polymer, where the first
region 14 has a greater rate of dissolution than the second region 15. In this
example, the rate of dissolution of the first region 14 is selected so that no
appreciable delay occurs in the release of the drug from the first part 16 of the core
11. The release of the drug from the first part of the core 11 is shown by the initial
steep linear rise in the fractional release as shown in Fig. 4. This time period
corresponds to the situation illustrated in Fig. 10B. When the first part 16 of the core
11 has been completely dissolved, the second part 17 begins to dissolve (Fig. 10C)
at a less rapid but still essentially linear rate as shown by the less steeply pitched
part of the curve of Fig. 4 until the drug from the second part 17 is completely
dissolved as shown in Fig. 10D. Different release rates of the drug may be
accomplished by different initial concentrations of the drug in each part 16, 17 or by
varying the excipients as known in the art.

A fifth embodiment of the present invention is described with respect to Figs.
5 and Figs. 11A-C. Fig. 5 is a graph of the release rate of a drug from the fifth
embodiment of the asymmetrically coated tablet of the present invention
superimposed on a graph of the release rate of a commercially-available
brand of pharmaceutical, Inderal® LA.

Figs. 11A-C are elevation sectional views of the fifth embodiment of the
asymmetrically coated tablet 10 of the present invention. This embodiment is similar
to the embodiments of Figs. 1-4 and 6, but the core 11 of the tablet 10 is made with
a water-insoluble polymer rather than the water-soluble polymers of Figs. 1-4 and 6.
By the use of water-insoluble polymers, the rate of the drug release is determined by
Fickian kinetics as known in the art and as shown in Fig. 5.

A sixth embodiment of the present invention is described with respect to Figs.
6 and Figs. 12A-C. Fig. 6 is a graph of the release rate of a drug from the sixth
embodiment of the asymmetrically coated tablet 10 of the present invention
superimposed on a graph of the release rate of a commercially-available
brand of pharmaceutical, Asacol®.

Figs. 12A-C are elevation sectional views of the sixth embodiment of the
asymmetrically coated tablet 10 of the present invention. In this embodiment, the
first coating region 14 is made of an enteric polymer which is soluble at an enteric pH
of 5.0 and higher. Depending on the thickness of the polymer in the first region 14,
the dissolution of the first region 14 is delayed until the tablet 10 has been exposed
to an enteric pH for a given period of time. After dissolution of the first region 14, the
core 11 dissolves at the rate shown in Fig. 6.

A suitable technique to manufacture the tablet 10 of the present invention is
known as dry powder coating. In this technique as shown in Fig. 13, a core 11 would
first be formed using techniques known in the art. A tool 20, shown in cross-section
in Fig. 13, having the desired cross-sectional shape would be placed on a lower die
21. The interior of the tool 20 is then filled with a first layer 22 of a powder to form
the coating for the first region 14. The core 11 is then placed on the first layer 22 of
powder. The remaining space in the tool 20 around and above the core 11 is then
filled with a second layer 23 of powder to form the second region 15 of the coating.
An upper die 24 is then used to compress the powders around the core 11 into the
asymmetrical coating for the tablet 10. Modifications to this process may be used to
produce varied embodiments of the present invention.
**Industrial Applicability**

The present invention uses asymmetrically coated tablets so that immediate release or time-delayed release times can be precisely controlled and the extended release tablet may provide zero-order or first-order extended release and pulsatile release depending on the excipients used in the tablet formulations. Immediate release or time-delayed release time can be precisely determined. Extended release kinetics can be manipulated as a dosage form designer wishes.

The present invention has been described with reference to certain preferred and alternative embodiments that are intended to be exemplary only and not limiting to the full scope of the present invention as set forth in the appended claims. For example, various combinations of the embodiments described can be employed to design a dosage form for whatever release kinetics are desired. Further, although the embodiments described above relate to a dosage form having zero-order kinetics, the present invention is not so limited.
Claims

1. An asymmetrically coated tablet for extended release of a drug, comprising:
   a core comprising a drug dispersed in at least one excipient; and
   a coating covering said core;
   wherein said coating comprises at least two regions, each of said regions having a drug release property that differs from the drug release property of any other region.

2. The tablet of claim 1, wherein said drug release property comprises a drug concentration.

3. The tablet of claim 1, wherein said drug release property comprises a rate of dissolution in a dissolution medium.

4. The tablet of claim 1, wherein said core comprises a uniform cross-sectional area.

5. The tablet of claim 4, further comprising a first region coating a portion of said core such that dissolution of said first region exposes said cross-sectional area of said core and a second region coating a remaining portion of said core.

6. The tablet of claim 5, wherein said first region comprises a water soluble polymer and said second region comprises a water insoluble polymer.

7. The tablet of claim 5, wherein said first region and said second region comprise water soluble polymers and wherein said first region has a rate of dissolution greater than a rate of dissolution of said second region.

8. The tablet of claim 5, wherein said first region further comprises a drug.

9. The tablet of claim 1, wherein said core comprises a first part and a second part, said first part having a first rate of dissolution and said second part having a different second rate of dissolution.

10. The tablet of claim 1, wherein said core comprises a water insoluble polymer.

11. The tablet of claim 5, wherein said first region comprises an enteric polymer.
FIG. 1

Fractional Release vs. Time (min)
**FIG. 3**

A plot showing the fractional release over time for Covera HS and UAMS.
FIG. 4
FIG. 5
FIG. 6

Fractional Release vs Time (min) at pH 7.4

- Asacol®
- UAMS
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC: A61K 9/20( 2006.01),9/28( 2006.01)
USPC: 424/464,465,467,472,474
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
U.S. : 424/464,465,467,472,474

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
east brs search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 4,606,909 A (BECHGAARD et al) 19 August 1986 (19/08 1986), column 3, lines 26- column 9, line 16</td>
<td>1-11</td>
</tr>
<tr>
<td>X</td>
<td>US 5,431,920 A (BECHARD) 11 July 1995 (11/07 1995), column 4, lines 17-column 6, lines 1</td>
<td>1-11</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

Date of the actual completion of the international search

Name and mailing address of the ISA/US
Mail Stop PCT, Attn ISA/US
Commissioner for Patents
P.O Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (571) 273-3201

Date of mailing of this International Search Report

See patent family annex.

Form PCT/ISA/210 (second sheet) (April 2005)